TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03980522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPL-914
Description: KPL-914 (rilonacept) will be provided in its commercially available formulation as a lyophilized powder to be reconstituted for SC administration.~Adult participants (≥ 18 years of age) KPL-914 will be administered as an initial loading dose of 320 mg SC, delivered as 2 subcutaneous injections of 160 mg SC each on Day 0, then 160 mg SC dosed once weekly for 5 subsequent weeks.~Pediatric participants (6 to \<18 years of age) KPL-914 will be administered with an initial loading dose of 4.4 mg/kg, up to a maximum of 320 mg, delivered as 2 subcutaneous injections of 2.2 mg/kg each with a maximum single-injection volume of 2 mL.~Participants considered to be 'treatment responders' will be offered participation in an optional 18-week extension period (EP) in which KPL-914 can be continued for a total duration of KPL-914 treatment of up to 24 weeks.
Study: NCT04423211

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluciclovine F18
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study: NCT02861989

Intervention type: OTHER
Intervention: qualitative study

Intervention type: OTHER
Intervention: qualitative study
Study: NCT04951232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinepazide Maleate
Description: The experimental group: guipiprazitel maleate injection (klingo): 320mg (4), dissolved in 500ml of normal saline, and injected in a medium vein at a rate of 100ml/h, once a day, and administered for 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 4 pieces, dissolved in normal saline 500ml, intravenous drip, the speed is 100ml / h, once a day, continuous administration for 14 days
Study: NCT00144027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication adherence intervention
Description: The medication adherence intervention will include using a computer to complete a brief set of questions related to medication adherence before mental health clinic visits.
Study: NCT01733069

Intervention type: DEVICE
Intervention: APTIMA COMBO 2 Assay (AC2 Assay)
Description: APTIMA COMBO 2 Assay (AC2 Assay
Study: NCT04530812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Maintain usual diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kefir
Description: Consume commercial kefir beverage
Study: NCT04423211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study: NCT04530812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04488692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early intervention (Mobility functional training)
Description: functional training focused on mobility (bed mobility, sitting balance, standing balance, and ambulation)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early intervention (Mobility functional training)
Description: functional training focused on mobility (bed mobility, sitting balance, standing balance, and ambulation)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham intervention
Description: friendly visit and education
Study: NCT04423211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Given IM

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volume Modulated Arc Therapy
Description: Undergo VMAT
Study: NCT03213704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo a bone marrow aspiration and/or biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo a bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib Sulfate
Description: Given PO or via nasogastric- or gastric-tube

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo a MIBG scintigraphy
Study: NCT03394664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feeding Study
Description: Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feeding Study
Description: Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feeding Study
Description: Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).
Study: NCT02114008

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic examinations
Description: Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test) and after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin). All patients received both oral and written information about the protocol at the outpatient clinic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic examinations
Description: Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test) and after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin). All patients received both oral and written information about the protocol at the outpatient clinic.
Study: NCT04521205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal microbiota capsule
Description: a capsule full of fecal microbiota extracting from the health
Study: NCT03542240

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 500 milligram daily supplement
Study: NCT01892254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, 2x 2 tablets a day, 500 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin, 2x 2 tablets a day, 500 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (to metformin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (to metformin)
Study: NCT03333785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eOncoNote
Description: * Diagnosis phase: The patient's nurse navigator will initiate an eOncoNote to the patient's PCP, inviting them to send any questions related to the patient's diagnostic process. The nurse navigator will initiate case closure after the diagnostic process has been completed (case will be open up to 4 months).~* Treatment phase: The patient's medical or radiation oncologist will initiate an eOncoNote to the patient's PCP inviting them to ask questions related to the patient's cancer treatment and/or request information related to the patient's co-morbidities. The oncologist will initiate case closure after the treatment has been completed.~* Survivorship phase: The patient's registered nurse within the Wellness Beyond Cancer Program will send an eOncoNote invitation to the patient's PCP inviting them to ask any questions as the patient transitions back to their care. The nurse will initiate case closure after one year.
Study: NCT01792622

Intervention type: OTHER
Intervention: Interview
Description: Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
Study: NCT01641016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: May be taken as 600mg tablet, 200mg tablet or as part of a combination pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
Study: NCT03593304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection Mecobalamin
Description: Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tablet Pyridoxine hydrochlorid
Description: Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Injection Normal saline(1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Placebo Oral Tablet (25 mg) 2 tablets thrice daily for 5 weeks.
Study: NCT01626638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Confocal Micro Endoscopy
Study: NCT01812590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT02602977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple-dose Remote Ischemic Preconditioning
Description: A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Multiple-dose RIPC consists of a daily dose of 1 RIPC as described above for 7 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-dose Remote Ischemic Preconditioning
Description: A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Single-dose RIPC consists of 1 dose of RIPC as described above

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LPS infusion
Description: To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group \[n=10\], single-dose RIPC group \[n=10\] and control group \[n=10\]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS infusion
Description: To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group \[n=10\], single-dose RIPC group \[n=10\] and control group \[n=10\]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS infusion
Description: To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group \[n=10\], single-dose RIPC group \[n=10\] and control group \[n=10\]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.
Study: NCT01936077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant LH (Luveris)
Description: 150 IU recombinant LH daily.
Study: NCT04672330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) before surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation）
Study: NCT02250027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL301 300mg capsule
Description: 2 capsules at once, 3 times a day, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL301 300mg capsule
Description: 2 capsules at once, 3 times a day, for 7 days
Study: NCT03213704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study: NCT04521205

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fecal microbiota capsule
Description: a capsule full of fecal microbiota extracting from the health
Study: NCT01070550

Intervention type: DRUG
Intervention: Peginterferon alfa-2a (Pegasys®)
Description: Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Study: NCT00818142

Intervention type: BEHAVIORAL
Intervention: ED/DM Support Group
Description: The ED/DM Recovery Group focuses on assisting individuals with diabetes and an eating disorder - specifically the struggle of withholding insulin. The group utilizes strategies and tools that have been taught in other EDI programs, and also builds on the strengths of a group. The group is a means for learning and support as the individuals continue a regular schedule of school, work, and/or family life.
Study: NCT03830801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVLCM tethered capsule
Description: Obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk using IVLCM tethered capsule
Study: NCT00500149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyvanse (lisdexamfetamine dimesylate)
Description: Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02298517

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: incentive spirometry
Description: Incentive spirometry to flow and incentive spirometry to volume
Study: NCT01712685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-VM4-037
Description: Drug being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Study: NCT00486915

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left Atrial Appendage Ligation
Study: NCT00180674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study: NCT03034317

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuRx DPS
Description: Patients who are diagnosed with ALS, have initiated NIV and choose to have the NeuRx DPS implanted.
Study: NCT01472627

Intervention type: PROCEDURE
Intervention: Blood draws
Description: Blood draws
Study: NCT04428086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib in arm1
Description: Apatinib will be administered at a dose of 250 mg once daily from Day 4 to Day 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib in arm2
Description: Apatinib will be administered at a dose of 250 mg once daily from Day 3 to Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be administered as a single oral 500 mg on Day 1 and Day 6.
Study: NCT02937844

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 CSR T cells
Description: Prescribed CSR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m\^2, d1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/m\^2, d1-3
Study: NCT06303830

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium nitrate
Description: Sodium Nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitrate
Description: Sodium Nitrate
Study: NCT02788136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin
Description: At 08 AM of day 0, all subjects underwent to a single intramuscular injection of hCG of 5000 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Description: At 08 AM of day 0, all subjects underwent to a single intramuscular injection of hCG of 5000 IU
Study: NCT03372486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plus naloxone
Description: Patients received 20 mL bupivacaine 0.5% plus 100 ng naloxone (1ml) in 2ml saline.(naloxone ampoule 0.4mg will dilute in 400ml of saline then 1ml of it will dilute in 10 ml saline, so each ml will have 100ng naloxone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Patients will be injected ultrasound guided in their brachial plexus by 20 mL bupivacaine 0.5% plus 3 ml of saline
Study: NCT00278564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Autologous hematopoietic stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG(rabbit)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Study: NCT06358742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZCT toothpaste

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control toothpaste
Study: NCT02628522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADRCs therapy
Description: Patients with chronic anal fissures will receive one treatment of local injections of fat enriched with adipose derived regenerative cells starting from December 2014.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celution
Description: Adipose derived regenerative cell isolation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tulip cannulas
Description: Lipoaspiration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20mL Lidocaine 2% and Epinephrine 1:100 000
Description: Infiltration prior to liposuction
Study: NCT03706833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards PASCAL System
Description: Transcatheter mitral valve repair with the Edwards PASCAL System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards PASCAL System
Description: Transcatheter mitral valve repair with the Edwards PASCAL System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards PASCAL System
Description: Transcatheter mitral valve repair with the Edwards PASCAL System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Mitraclip System
Description: Transcatheter mitral valve repair with the Abbott Mitraclip System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Mitraclip System
Description: Transcatheter mitral valve repair with the Abbott Mitraclip System
Study: NCT03382873

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Lifestyle Balance (GLB)
Description: The intervention included the following key features: group-based sessions led by a lifestyle coach; a structured, state-of-the-art, 16-session core-curriculum that emphasized behavioral self-management strategies for weight loss and physical activity; 8-months of extended care with bimonthly or monthly sessions; self-monitoring of diet and physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance Plus (GLB+)
Description: The GLB+ intervention arm included participants who did not achieve the targeted percent weight loss by week 5 and incorporated enhanced training in values clarification, mindful decision making, planning, and problem solving. GLB+ included the same number of group-based sessions as GLB.
Study: NCT00576602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Recommended starting dose of 0.6 micrograms/kg sc every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supportive treatment
Description: As prescribed
Study: NCT04289285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI306 450mg SC Q4W
Description: Subjects will receive IBI306 450mg every 4 weeks subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC Q4W
Description: Subjects will receive placebo every 4 weeks subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI306 600mg SC Q6W
Description: Subjects will receive IBI306 600mg every 6 weeks subcutaneously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC Q6W
Description: Subjects will receive placebo every 6 weeks subcutaneously.